-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $40

Benzinga·01/08/2026 17:26:36
语音播报
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $41 to $40.